{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:00:12Z","timestamp":1773032412419,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpedhc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Health Care"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.pedhc.2022.05.003","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T19:57:17Z","timestamp":1660766237000},"page":"479-488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0855-9875","authenticated-orcid":false,"given":"Juan Carlos","family":"Lopez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine R.","family":"Pare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison B.","family":"Blackmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1173-2146","authenticated-orcid":false,"given":"Lucas E.","family":"Orth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pedhc.2022.05.003_bib0001","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group","volume":"335","author":"Abenhaim","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0002","unstructured":"Biocodex, Inc. (2018). Diacomit (stiripentol): Highlights of prescribing information. Beauvais, France, Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206709s000, 207223s000lbl.pdf"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0003","article-title":"Epidiolex now available in the us as a noncontrolled substance","author":"Chapman","year":"2020","journal-title":"Dravet Syndrome News. Retrieved from"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0004","unstructured":"Charlie Foundation. (2021). KetoDietCalculator. Retrieved from https:\/\/www.ketodietcalculator.org\/ketoweb\/KetoStart"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/1060028018822124","article-title":"Cannabidiol: A New Hope for patients with Dravet or Lennox-Gastaut syndromes","volume":"53","author":"Chen","year":"2019","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.734612","article-title":"Treatment guidelines for rare, early-onset, treatment-resistant epileptic conditions: A literature review on Dravet syndrome, Lennox-Gastaut syndrome and CDKL5 Deficiency Disorder","volume":"12","author":"Chin","year":"2021","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0007","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: A randomised placebo-controlled syndrome-dedicated trial","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0008","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0009","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eplepsyres.2016.10.006","article-title":"Mortality in Dravet syndrome","volume":"128","author":"Cooper","year":"2016","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0010","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/acn3.51306","article-title":"Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder","volume":"8","author":"Devinsky","year":"2021","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0011","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/epi.14628","article-title":"Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial","volume":"60","author":"Devinsky","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0012","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0013","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0014","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0015","unstructured":"Eisai Medical. (2020). A study of Lorcaserin as adjunctive treatment in participants with Dravet syndrome (MOMENTUM 1). Retrieved from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04572243"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0017","unstructured":"Food and Drug Administration. (2019). Novel drug approvals for 2018. Retrieved from https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2018"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0018","unstructured":"Food and Drug Administration. (2021a). FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD). Retrieved from https:\/\/www.fda.gov\/news-events\/public-health-focus\/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0019","unstructured":"Food and Drug Administration. (2021b). Novel drug approvals for 2020. Retrieved from https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2020"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0020","unstructured":"Food and Drug Administration & Center for Drug Evaluation and Research. (2020). Diacomit clinical review. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/206709Orig1s000,207223Orig1s000MedR.pdf"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0021","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0023","unstructured":"Greenwich Biosciences, Inc. (2021). Frequently asked questions. Retrieved from https:\/\/www.epidiolexhcp.com\/resources\/frequently-asked-questions"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0022","unstructured":"Greenwich Biosciences, Inc. (2018). Epidiolex (cannabidiol): Highlights of prescribing information. Carlsbad, CA, Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210365lbl.pdf."},{"key":"10.1016\/j.pedhc.2022.05.003_bib0025","unstructured":"IBM. (2021). Watson health. Stiripentol: Adverse Effects [Electronic version]. Retrieved from https:\/\/www.micromedexsolutions.com\/ [subscription required]"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0026","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.eplepsyres.2015.03.012","article-title":"Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan","volume":"113","author":"Inoue","year":"2015","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0051","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamaneurol.2021.2480","article-title":"Suicidality Risk of Newer Antiseizure Medications: A Meta-analysis","volume":"78","author":"Klein","year":"2021","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0027","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40263-018-0511-y","article-title":"Treatment strategies for Dravet syndrome","volume":"32","author":"Knupp","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0028","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0029","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0030","series-title":"Cannabidiol","year":"2022"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0031","series-title":"Fenfluramine","year":"2022"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0032","series-title":"Stiripentol","year":"2022"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0033","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1056\/NEJM199708283370904","article-title":"Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine","volume":"337","author":"Mark","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106989","article-title":"Fenfluramine acts as a positive modulator of sigma-1 receptors","volume":"105","author":"Martin","year":"2020","journal-title":"Epilepsy and Behavior: E&B"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0035","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/FTD.0b013e31825dc4a6","article-title":"Concentrations of stiripentol in children and adults with epilepsy: The influence of dose, age, and comedication","volume":"34","author":"May","year":"2012","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0036","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: A randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0037","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/dmcn.13704","article-title":"Stiripentol efficacy and safety in Dravet syndrome: A 12-year observational study","volume":"60","author":"Myers","year":"2018","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"Suppl. 1","key":"10.1016\/j.pedhc.2022.05.003_bib0038","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.ejpn.2012.04.009","article-title":"Stiripentol: An example of antiepileptic drug development in childhood epilepsies","volume":"16","author":"Nabbout","year":"2012","journal-title":"European Journal of Paediatric Neurology"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0039","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: A randomized clinical trial","volume":"77","author":"Nabbout","year":"2020","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0040","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.yebeh.2018.08.021","article-title":"Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome","volume":"91","author":"Polster","year":"2019","journal-title":"Epilepsy and Behavior: E&B"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0041","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/epi.17036","article-title":"Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial","volume":"62","author":"Scheffer","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0042","unstructured":"Segal, E., Wheless, J., & Keough, K. (2020). EPX-100 (clemizole hydrochloride) as add-on therapy to control convulsive seizures in patients with Dravet syndrome (ARGUS). Retrieved from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04462770"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0043","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/14737175.2020.1801423","article-title":"Therapeutic advances in Dravet syndrome: A targeted literature review","volume":"20","author":"Strzelczyk","year":"2020","journal-title":"Expert Review of Neurotherapeutics"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0044","unstructured":"Takeda Pharma. (2021). A study of soticlestat as an add-on therapy in children and young adults with Dravet syndrome. Retrieved from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04940624"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0045","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0046","unstructured":"Wical, B. (2012). Verapamil as therapy for children and young adults with Dravet syndrome. Retrieved from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01607073"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0047","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2017.01.025","article-title":"Optimizing the diagnosis and management of Dravet syndrome: Recommendations from a North American consensus panel","volume":"68","author":"Wirrell","year":"2017","journal-title":"Pediatric Neurology"},{"key":"10.1016\/j.pedhc.2022.05.003_bib0050","unstructured":"Zogenix, Inc. (2020). Fintepla (fenfluramine): Highlights of prescribing information. Emeryville, CA, Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212102s000lbl.pdf."},{"key":"10.1016\/j.pedhc.2022.05.003_bib0049","unstructured":"Zogenix, Inc. (2021). What is the FINTEPLA REMS (Risk Evaluation and Mitigation Strategy)? Retrieved from https:\/\/www.finteplarems.com\/Public\/Default\/prescribers"}],"container-title":["Journal of Pediatric Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891524522001080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891524522001080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:10:14Z","timestamp":1760195414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891524522001080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0891524522001080"],"URL":"https:\/\/doi.org\/10.1016\/j.pedhc.2022.05.003","relation":{},"ISSN":["0891-5245"],"issn-type":[{"value":"0891-5245","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Health Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pedhc.2022.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 by the National Association of Pediatric Nurse Practitioners. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}